Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $16.072 million which beat the analyst consensus estimate of $5.995 million by 168.09 percent. This is a 112.68 percent increase over sales of $7.557 million the same period last year.